Deep Tech Startups

Brain-CA Technologies develops an energy-efficient AI architecture based on Cellular Automata, designed to perform AI/ML tasks with lower power consumption and faster learning than existing systems. The company is building a software prototype of its patented algorithms with plans to develop an AI hardware chipset.

2 investors

Braintrance is a platform for sharing and viewing immersive 3D and spatial media, including Gaussian splats, 360 and 180 photos and videos, GLB scenes, and panoramas. Users upload and browse spatial content organized into categories.

2 investors

Brandon BioCatalyst funds biomedical development opportunities associated with its Member Institutes, offering investments ranging from AU$500,000 to AU$30 million across stages from proof-of-concept to late-stage technologies. It operates an investment process through an Investment Review Committee, with due diligence handled by Brandon Capital.

2 investors

Breathe develops a battery software toolchain that lets OEMs and battery engineering teams design, simulate, and control lithium batteries to improve cycle life, energy density, and charging while lowering costs. Its tools target automakers and other device manufacturers rather than providing battery management hardware.

2 investors

Bridger Photonics develops Gas Mapping LiDAR technology and analytics to detect and measure methane emissions from oil and gas operations, helping operators reduce emissions, cut costs, and meet regulatory requirements.

2 investors

Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections. It designs fungal-selective inhibitors targeting fungal stress responses, using Schrödinger's computational drug discovery platform alongside its own proprietary technologies.

2 investors

Brighter Signals develops proprietary fabric-based tactile sensing technology that measures both the sensitivity and density of touch in a single sensor, enabling occupancy detection and movement analysis. The company serves applications requiring advanced pressure and strain monitoring, offering fabrics, sensors, and accompanying hardware and software solutions.

2 investors

Brinter develops 3D bioprinting technology for regenerative implants. The company serves the medical and biotech industries focused on human repair applications.

2 investors

Briteseed develops hyperspectral imaging technology integrated into laparoscopic and robotic surgical instruments to provide real-time visualization of critical anatomical structures during surgery. The company produces a suite of surgical tools including energy, stapler, and dissection instruments that display information on existing operating room monitors to improve surgical safety and outcomes.

2 investors

A company addressing quantum computing security threats by helping organizations protect long-term sensitive information and intellectual property.

2 investors

Bubble Robotics builds autonomous underwater robots and AI ("Physical AI") for persistent monitoring, mapping, and inspection of offshore assets and subsea infrastructure such as energy installations and data cables. The company applies expertise from autonomous space and planetary robotics to ocean operations, serving offshore industries.

2 investors

Bugworks Research is a drug discovery company developing small molecule therapeutics, including novel antibacterial agents targeting antimicrobial resistance (AMR) across Gram-negative and Gram-positive infections and next-generation immuno-oncology treatments for hard-to-treat tumors. Its research focuses on affordable oral and intravenous therapies for serious hospital and community infections and cancer.

2 investors

Bunsen is a creative agency that helps science and deep technology companies develop strategic narratives and design to communicate their innovations to investors and the public. The firm combines scientific expertise, venture capital insight, and creative design to serve founders in biotech, life sciences, and frontier technology sectors.

2 investors

C2GRID builds a geospatial awareness and decision-support platform that converts video, including drone footage, into near real-time 3D operational environments with multi-sensor data fusion and automated threat detection. It serves military operators and defence and security organisations, with the team also exploring civilian applications such as emergency response, infrastructure monitoring, and industrial inspection.

2 investors

CaaMTech is a pharmaceutical drug discovery company that engineers novel small-molecule psychedelic-inspired therapeutics for mental health treatment through structure-activity optimization and safety screening. The company conducts fundamental research on tryptamine compounds, develops intellectual property, and aims to support the psychedelics industry with scientific foundations and validated drug candidates.

2 investors

Caffree develops a powdered enzymatic system for precision decaffeination that converts caffeine into theobromine, allowing coffee brands to control caffeine levels without changing flavor. It targets coffee brands, cold brew and RTD beverage manufacturers, and co-packers, integrating into existing production equipment.

2 investors

CalTa develops digital twin technology, including its TRANCITY platform and related tools, for managing and inspecting social infrastructure such as railways, roads, ports, water systems, and plants. Founded by engineers from the railway industry, it uses 3D data to help field workers inspect and make decisions about infrastructure maintenance in Japan.

2 investors

Calyos designs and produces passive two-phase cooling systems—including micro/pulsating heat pipes, oscillating heat pipes, traditional heat pipes, and loop heat pipes—for high-performance thermal management of electronics, batteries, and power components. It serves the electric mobility, data center/AI computing, energy storage, and aerospace and defense markets.

2 investors

CDT is a research and innovation centre focused on developing advanced materials, particularly polymer OLED and next-generation display technologies, with a heritage rooted in Cambridge University spin-out research since 1989. The organization provides R&D support and strategic funding to early-stage companies, leveraging its parent company Sumitomo Chemical's global resources to commercialize scientific innovations.

2 investors

Canopus develops directional steel shot drilling (DSSD) technology for constructing geothermal wells and borehole heat exchangers at shallow, deep, and ultra deep depths. Its products include the Canoctopus system of curved borehole heat exchangers and multilateral well structures for geothermal heating, cooling, and energy production.

2 investors

Canurta develops novel botanical drug candidates, starting with rare polyphenols, using an AI discovery engine that guides compound identification, optimization, GMP-compliant production, and blockchain-based traceability. The company targets disease pathways such as inflammation, oxidative stress, and neurodegeneration (including ALS) across its therapeutic pipeline.

2 investors

Canyon Magnet Energy is a fusion energy company focused on developing technology related to controlled nuclear fusion as a clean, high-density energy source. The site discusses fusion reactor approaches such as tokamaks and stellarators and the path toward a U.S. pilot fusion power plant.

2 investors

CapyBio provides tools to measure how closely cells match a target identity and to improve them, helping scientists and biopharma teams reduce failure in drug discovery, build stronger disease models, and advance cell-based therapies. The company applies cell biology and computational methods to cell identity for research, testing, and regenerative medicine.

2 investors

Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.

2 investors